Sarecycline hydrochloride for the treatment of acne vulgaris.

Kaul, G; Saxena, D; Dasgupta, A; Chopra, S

Kaul, G; Saxena, D; Dasgupta, A; Chopra, S.

Affiliation

Kaul G; Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Saxena D; Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Dasgupta A; Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Chopra S; Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India. skchopra007@gmail.com.

Drugs Today (Barc) ; 55(10): 615-625, 2019 Oct.

Article in En | MEDLINE | ID: mdl-31720559

Subject(s)

Acne Vulgaris/drug therapy; Anti-Bacterial Agents/therapeutic use; Dermatologic Agents/therapeutic use; Tetracyclines/therapeutic use; Drug Approval; Humans; United States; United States Food and Drug Administration

Key words

Acne therapy; Acne vulgaris; Antibacterial drugs; Cutibacterium acnes; Dermatologic drugs; Endogenous intestinal microbial flora; Sarecycline hydrochloride; Tetracyclines

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tetracyclines / Acne Vulgaris / Dermatologic Agents / Anti-Bacterial Agents Limits: Humans Country/Region as subject: America do norte Language: En Journal: Drugs Today (Barc) Journal subject: MEDICINA OCUPACIONAL / SAUDE AMBIENTAL Year: 2019 Document type: Article Affiliation country: India Country of publication: Spain

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google